Editas Medicine, Inc.
(NASDAQ : EDIT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.29%80.010.9%$592.45m
CELGCelgene Corporation
-1.44%136.861.1%$550.39m
AMGNAmgen Inc.
-0.13%185.941.1%$449.23m
BIIBBiogen Inc.
0.20%345.171.2%$387.27m
REGNRegeneron Pharmaceuticals, Inc.
-1.34%436.612.7%$313.67m
ALNYAlnylam Pharmaceuticals, Inc
-1.87%116.4910.7%$251.54m
VRTXVertex Pharmaceuticals Incorporated
-0.28%154.611.9%$220.82m
INCYIncyte Corporation
-0.41%115.172.5%$207.12m
ALXNAlexion Pharmaceuticals, Inc.
-1.89%140.451.9%$178.59m
ILMNIllumina, Inc.
-0.25%205.963.5%$139.52m
EXELExelixis, Inc.
-2.03%27.736.5%$132.71m
CLVSClovis Oncology, Inc.
-2.48%79.3116.5%$121.60m
BLUEBluebird Bio, Inc.
-1.28%138.4017.3%$116.60m
SRPTSarepta Therapeutics, Inc.
-0.07%51.6916.9%$109.96m
BMRNBioMarin Pharmaceutical Inc.
-4.41%89.424.4%$98.94m

Company Profile

Editas Medicine, Inc. engages in the development and commercialization of genome editting technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu on September 3, 2013 and is headquartered in Cambridge, MA.^ ^ ^